Abbott Informatics contribution to the COVID-19 response

We are developing digital solutions to enable labs and healthcare settings to implement COVID-19 testing and reporting
 
STARLIMS solution

STARLIMS  helps labs with
covid-19 testing

 

Abbott Informatics’ Laboratory Information Management System collects, manages and reports lab data rapidly and seamlessly. STARLIMS offers a range of digital solutions to address the needs and challenges of laboratories, as well as non-traditional healthcare settings that use of point of care testing.

Since the beginning of the pandemic, Abbott Informatics has been actively working with various customers within the Public Health sector including CDC, to assist with COVID-19 test workflow configuration, instrument interfaces, streamline the COVID-19 sample collection and reception processes, and reporting to Public Health.

STARLIMS solution key benefits

Reduce Overall Turnaround Time and Lab Operation Costs

Faster Implementation and Validation

  • Cloud based ready-to-use and ready-to-configure solutions
  • Easy to configure instrument interfaces such as: M2000, Alinity i, ABI7500, Quantstudio, Panther Fusion, Cobas 6800/8000, Xpert Xpress, among others
  • Support for pre-configured COVID-19 testing workflows
  • Validated HL7 interfaces for Public Health reporting compliant with CARES Act Section 18115, in partnership with AIMS (APHL Informatics Messaging Services)

Reduce Manual Entry Errors

  • Web Portal and Mobile Solution for real time sample collection eliminates the need for manual data entry registration
  • Mobile Solution with Driver’s License and State ID scanning capabilities to capture patient demographics
  • Automated instrument interfaces

Be Compliant with CARES ACT SECTION 18115

  • Capture all required patient testing data including questions for COVID-19 testing
  • Automated reporting for reporting to Public Health Authorities based on the patient’s state of residence 
  • Validated HL7 interfaces for Public Health reporting compliant with CARES Act Section 18115, in partnership with AIMS (APHL Informatics Messaging Services)

Increase Testing Capacity

  • Support for pooling testing workflows
  • Minimum configuration for adding new instrument interfaces

 
 
One Abbott Solution

The ONE ABBOTT SOLUTION FOR
ID NOW COVID-19 TESTING

The One Abbott Solution1 for ID NOW COVID-19 testing is a simple, reliable and secure end-to-end connectivity and reporting solution. It offers speed and performance for ID NOW™2 COVID-19 testing and reporting within 24 hours3 for decentralized environments to help you manage data without infrastructure burden.

Download brochure

Testing patients at the point of care

The ID NOW™ platform, the most widely-used point-of-care molecular device for COVID-19 detection provides results in 13 minutes or less. It is also portable and allows use in any patient care setting, including decentralized locations.

Capturing results without manual entry

RALS™ LiNK connectivity tracks, captures and consolidates patient results from multiple ID NOW™ instruments and sends data to the STARLIMS Digital Solution with no manual entry. It also provides customizable dashboards which give you access to ID NOW™ COVID-19 testing data and analytics.

Capturing and reporting demographics in near real time

STARLIMS Digital Solution collects ordering physician data, patient questions and test results for ID NOW™ COVID-19 testing, and reports this data accurately to public health local and federal authorities within 24 hours.

Learn more about Abbott's ID Now.

Learn more about Abbott's RALS LiNK.

Listen to a timely educational webinar on the CARES Act, information gathering, and test reporting for COVID-19 testing sites.

1Only available in the US. 2The ID NOW™ COVID-19 EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. 3Reporting services may not be available in certain States.

one-abbott-solution-for-idnow-covid19.jpg

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

Request a
Demo